{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-097921","form_type":"8-K","ticker":"IRMD","cik":"0001325618","company_name":"IRADIMED CORP","filed_at":"2021-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.627591+00:00","generated_at":"2026-06-30T00:17:37.813719+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"iRadimed Q2 2021 revenue $9.8M, GAAP EPS $0.12; guides FY21 rev $40.0-40.4M","bullets":["Q2 2021 revenue $9.8M, up 44% YoY from $6.8M; net income $1.5M vs net loss of $2.1M.","GAAP diluted EPS $0.12; non-GAAP diluted EPS $0.14, up from $0.05 in Q2 2020.","Q3 2021 guidance: rev $10.3-10.5M, GAAP EPS $0.14-0.15, non-GAAP EPS $0.16-0.17.","Full-year 2021 guidance: rev $40.0-40.4M, GAAP EPS $0.53-0.55, non-GAAP EPS $0.60-0.62.","Cash and investments $56.1M at quarter-end; operating cash flow $4.5M YTD."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-097921","json":"https://secwatch.observer/filing/0001104659-21-097921.json","markdown":"https://secwatch.observer/filing/0001104659-21-097921.md","text":"https://secwatch.observer/filing/0001104659-21-097921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1325618/000110465921097921/0001104659-21-097921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1325618/000110465921097921/tm2123649d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T00:17:37.813719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}